Expression profile of ovarian tumors: Distinct signature of Sertoli-Leydig cell tumor

International Journal of Gynecological Cancer

Volumn 16, Issue 6, 2006, Pages 1963-1972

  Baranova, A ^a   Gowder, S ^a,b   Naouar, S ^a   King, S ^a,b   Schlauch, K ^a,c   Jarrar, M ^a   Ding, Y ^a,b   Cook, B ^a   Chandhoke, V ^a   Christensen, A ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b AMERICAN TYPE CULTURE COLLECTION   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cDNA microarray; Expression profiling; Ovarian carcinoma; Sertoli Leydig tumor

Indexed keywords

COMPLEMENTARY DNA; SONIC HEDGEHOG PROTEIN;

AMINO ACID METABOLISM; ANDROBLASTOMA; ARTICLE; CANCER GENETICS; COMPARATIVE STUDY; DNA MICROARRAY; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN SYNTHESIS; UNINDEXED SEQUENCE;

FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SERTOLI-LEYDIG CELL TUMOR;

EID: 33845525187     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00732.x     Document Type: Article

References (27)

1. Dupont NC, Berman ML. Surgical management of epithelial ovarian cancer: a review of the literature. Minerva Ginecol 2004;56:547-56.
2. Seidman JD, Kurman RJ. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 2003;4:909-25.
3. Appetecchia M, Cela V, Bernardi F, Burelli A, Cionini R, Pucci E. Sertoli-Leydig cell androgens-estrogens secreting tumor of the ovary: ultra-conservative surgery. Eur J Obstet Gynecol Reprod Biol 2004;116:113-6.
4. Phadke DM, Weisemberg E, Engel G, Rhone DP. Malignant Sertoli cell tumor of the ovary metastatic to the lung mimicking neuroendocrine carcinoma: report of a case. Ann Diagn Pathol 1999;4:213-9.
5. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IeM. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004;64:6915-8.
6. Chen T, Triplett J, Dehner B, Hurst B et al. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 2001;12:4679-82.
7. De Cecco L, Marchionni L, Gariboldi M et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 2004;49:8171-83.
8. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;18:6768-76.
9. Shridhar V, Lee J, Pandita A et al. Genetic analysis of early-versus late-stage ovarian tumors. Cancer Res 2001;61:5895-904.
10. Wenham RM, Lancaster JM, Berchuck A. Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002;4:483-97.
11. Schwartz DR, Kardia SL, Shedden KA et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;16:4722-9.
12. Grant GM, Fortney A, Gorreta F et al. Microarrays in cancer research. Anticancer Res 2004;24:441-8.
13. Baranova A, Collantes R, Gowder SJ et al. Obesity-related differential gene expression in the visceral adipose tissue. Obes Surg 2005;6:758-65.
14. Gorreta F, Barzaghi D, VanMeter AJ, Chandhoke V, Del Giacco L. Development of a new reference standard for microarray experiments. Biotechniques 2004;6:1002-9.
15. Mayburd AL, Martlinez A, Sackett D et al. Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886. Clin Cancer Res 2006;12:1820-7.
16. Chan JK, Zhang M, Kaleb V et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary - a multivariate analysis. Gynecol Oncol 2005;1:204-9.
17. Hopfer O, Zwahlen D, Fey MF, Aebi S. The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 2005;93:709-18.
18. Artavanis-Tsakonas S, Rand M, Lake R. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
19. Tsuda L, Nagaraj R, Zipursky SL, Banerjee U. An EGFR/Ebi/Sno pathway promotes delta expression by inactivating Su (H)/SMRTER repression during inductive notch signaling. Cell 2002;5:625-37.
20. Okajima T, Xu A, Irvine KD. Modulation of notch-ligand binding by protein O-fucosyltransferase 1 and fringe. J Biol Chem 2003;43:42340-5.
21. Johnstone RW, Wang J, Tommerup N, Vissing H, Roberts T, Shi Y. Ciao 1 is a novel WD40 protein that interacts with the tumor suppressor protein WT1. J Biol Chem 1998;18:10880-7.
22. Srichai MB, Konieczkowski M, Padiyar A et al. A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus. J Biol Chem 2004;14:14398-408.
23. Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 2004;30:5131-7.
24. Conrotto P, Valdembri D, Corso S et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 2005;11:4321-9.
25. Saucier C, Khoury H, Lai KM, Peschard P, Dankort D, Naujokas. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sci U S A 2004;8:2345-50.
26. Sievers S, Alemazkour K, Zahn S et al. IGF2/H19 imprinting analysis of human germ cell tumors (GCTs) using the methylationsensitive single-nucleotide primer extension method reflects the origin of GCTs in different stages of primordial germ cell development. Genes Chromosomes Cancer 2005;3:256-64.
27. Welsh JB, Zarrinkar PP, Sapinoso LM et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001;3:1176-81.